Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company dedicated to developing innovative oral medicines through targeted protein degradation, a next-generation therapeutic modality that leverages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The company's website is www.kymeratx.com.

The company operates as a discovery and development organization focused on addressing targets that have historically been difficult to drug using conventional therapeutic approaches. Kymera's core competency lies in targeted protein degradation technology, which enables the development of small molecule therapeutics capable of targeting proteins without catalytic function, such as scaffolding proteins and transcription factors. This approach offers potential advantages over traditional therapeutics, including the possibility of oral dosing, reduced dosing frequency, and lower manufacturing costs compared to biologic therapies.

Kymera's primary focus is on immunology, where the company estimates more than 160 million patients in the United States, Europe, and Japan suffer from immune-inflammatory diseases that its programs could address. The company's disclosed pipeline includes three main immunology programs: STAT6, targeting Type 2 inflammation in allergic and atopic diseases; IRF5, addressing autoimmune and inflammatory conditions; and IRAK4, developed in collaboration with Sanofi for IL-1R and toll-like receptor-driven diseases. Additionally, Kymera entered into a collaboration with Gilead Sciences in June 2025 to develop molecular glue degraders targeting cyclin-dependent kinase 2 for oncology applications.

The company's lead program, KT-621, is being evaluated in Phase 2b clinical trials for atopic dermatitis and asthma. KT-579, the IRF5 program candidate, recently entered Phase 1 testing. Kymera does not operate its own manufacturing facilities and relies on third-party contract manufacturing organizations for drug substance and finished product production. The company positions itself as a leader in targeted protein degradation technology with a disease-agnostic discovery approach aimed at becoming a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines.